

# Myasthenia Gravis-North America Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/ME9B72369498EN.html>

Date: May 2018

Pages: 142

Price: US\$ 3,480.00 (Single User License)

ID: ME9B72369498EN

## Abstracts

### Report Summary

Myasthenia Gravis-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Myasthenia Gravis industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Myasthenia Gravis 2013-2017, and development forecast 2018-2023

Main market players of Myasthenia Gravis in North America, with company and product introduction, position in the Myasthenia Gravis market

Market status and development trend of Myasthenia Gravis by types and applications

Cost and profit status of Myasthenia Gravis, and marketing status

Market growth drivers and challenges

The report segments the North America Myasthenia Gravis market as:

North America Myasthenia Gravis Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

United States

Canada

Mexico

North America Myasthenia Gravis Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Drug Treatment  
Rapid Immunotherapies

North America Myasthenia Gravis Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)  
Hospitals  
Clinics  
Other

North America Myasthenia Gravis Market: Players Segment Analysis (Company and Product introduction, Myasthenia Gravis Sales Volume, Revenue, Price and Gross Margin):

Shire  
F. Hoffmann-La Roche  
CSL Behring  
Grifols  
Alexion Pharmaceutical  
Avadel Pharmaceuticals  
Baxter International  
Novartis  
Valeant Pharmaceuticals International  
Takeda Pharmaceutical Company

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF MYASTHENIA GRAVIS**

- 1.1 Definition of Myasthenia Gravis in This Report
- 1.2 Commercial Types of Myasthenia Gravis
  - 1.2.1 Drug Treatment
  - 1.2.2 Rapid Immunotherapies
- 1.3 Downstream Application of Myasthenia Gravis
  - 1.3.1 Hospitals
  - 1.3.2 Clinics
  - 1.3.3 Other
- 1.4 Development History of Myasthenia Gravis
- 1.5 Market Status and Trend of Myasthenia Gravis 2013-2023
  - 1.5.1 North America Myasthenia Gravis Market Status and Trend 2013-2023
  - 1.5.2 Regional Myasthenia Gravis Market Status and Trend 2013-2023

### **CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Myasthenia Gravis in North America 2013-2017
- 2.2 Consumption Market of Myasthenia Gravis in North America by Regions
  - 2.2.1 Consumption Volume of Myasthenia Gravis in North America by Regions
  - 2.2.2 Revenue of Myasthenia Gravis in North America by Regions
- 2.3 Market Analysis of Myasthenia Gravis in North America by Regions
  - 2.3.1 Market Analysis of Myasthenia Gravis in United States 2013-2017
  - 2.3.2 Market Analysis of Myasthenia Gravis in Canada 2013-2017
  - 2.3.3 Market Analysis of Myasthenia Gravis in Mexico 2013-2017
- 2.4 Market Development Forecast of Myasthenia Gravis in North America 2018-2023
  - 2.4.1 Market Development Forecast of Myasthenia Gravis in North America 2018-2023
  - 2.4.2 Market Development Forecast of Myasthenia Gravis by Regions 2018-2023

### **CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole North America Market Status by Types
  - 3.1.1 Consumption Volume of Myasthenia Gravis in North America by Types
  - 3.1.2 Revenue of Myasthenia Gravis in North America by Types
- 3.2 North America Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in United States
  - 3.2.2 Market Status by Types in Canada

- 3.2.3 Market Status by Types in Mexico
- 3.3 Market Forecast of Myasthenia Gravis in North America by Types

## **CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Myasthenia Gravis in North America by Downstream Industry
- 4.2 Demand Volume of Myasthenia Gravis by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Myasthenia Gravis by Downstream Industry in United States
  - 4.2.2 Demand Volume of Myasthenia Gravis by Downstream Industry in Canada
  - 4.2.3 Demand Volume of Myasthenia Gravis by Downstream Industry in Mexico
- 4.3 Market Forecast of Myasthenia Gravis in North America by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MYASTHENIA GRAVIS**

- 5.1 North America Economy Situation and Trend Overview
- 5.2 Myasthenia Gravis Downstream Industry Situation and Trend Overview

## **CHAPTER 6 MYASTHENIA GRAVIS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA**

- 6.1 Sales Volume of Myasthenia Gravis in North America by Major Players
- 6.2 Revenue of Myasthenia Gravis in North America by Major Players
- 6.3 Basic Information of Myasthenia Gravis by Major Players
  - 6.3.1 Headquarters Location and Established Time of Myasthenia Gravis Major Players
  - 6.3.2 Employees and Revenue Level of Myasthenia Gravis Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 MYASTHENIA GRAVIS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Shire
  - 7.1.1 Company profile
  - 7.1.2 Representative Myasthenia Gravis Product
  - 7.1.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Shire

## 7.2 F. Hoffmann-La Roche

### 7.2.1 Company profile

### 7.2.2 Representative Myasthenia Gravis Product

### 7.2.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche

## 7.3 CSL Behring

### 7.3.1 Company profile

### 7.3.2 Representative Myasthenia Gravis Product

### 7.3.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of CSL Behring

## 7.4 Grifols

### 7.4.1 Company profile

### 7.4.2 Representative Myasthenia Gravis Product

### 7.4.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Grifols

## 7.5 Alexion Pharmaceutical

### 7.5.1 Company profile

### 7.5.2 Representative Myasthenia Gravis Product

### 7.5.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Alexion Pharmaceutical

## 7.6 Avadel Pharmaceuticals

### 7.6.1 Company profile

### 7.6.2 Representative Myasthenia Gravis Product

### 7.6.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Avadel Pharmaceuticals

## 7.7 Baxter International

### 7.7.1 Company profile

### 7.7.2 Representative Myasthenia Gravis Product

### 7.7.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Baxter International

## 7.8 Novartis

### 7.8.1 Company profile

### 7.8.2 Representative Myasthenia Gravis Product

### 7.8.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Novartis

## 7.9 Valeant Pharmaceuticals International

### 7.9.1 Company profile

### 7.9.2 Representative Myasthenia Gravis Product

### 7.9.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International

## 7.10 Takeda Pharmaceutical Company

### 7.10.1 Company profile

- 7.10.2 Representative Myasthenia Gravis Product
- 7.10.3 Myasthenia Gravis Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MYASTHENIA GRAVIS**

- 8.1 Industry Chain of Myasthenia Gravis
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MYASTHENIA GRAVIS**

- 9.1 Cost Structure Analysis of Myasthenia Gravis
- 9.2 Raw Materials Cost Analysis of Myasthenia Gravis
- 9.3 Labor Cost Analysis of Myasthenia Gravis
- 9.4 Manufacturing Expenses Analysis of Myasthenia Gravis

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF MYASTHENIA GRAVIS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source

- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Myasthenia Gravis-North America Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/ME9B72369498EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ME9B72369498EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970